No End In Sight For M&A As Medtechs Adapt To The “New Normal”
Executive Summary
The global medtech industry may be facing slow growth, rising regulatory demands and not exactly free-flowing venture capital investment. But EY finds reasons for optimism and sees opportunities for companies able to cope with the changes and move with alacrity.